nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.04.2011 | Original Article

Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract

verfasst von: Kang Su Cho, Jae Young Joung, Ho Kyung Seo, In-Chang Cho, Han Soo Chung, Jinsoo Chung, Kang Hyun Lee

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Little information is available about changes in renal function after cisplatin-based chemotherapy (CBCT) in patients with a solitary kidney. The authors evaluated the renal safety and efficacy of CBCT after nephroureterectomy for upper urinary tract-urothelial carcinoma (UUT-UC).

Methods

The data of patients who underwent nephroureterectomy for UUT-UC and received CBCT for adjuvant and/or palliative treatment were reviewed. Renal function changes and renal function–related adverse events (AEs) were analyzed, and objective tumor responses were assessed.

Results

Sixty patients were enrolled, and a median of 6 cycles (1–22) of CBCT were administered. After the 3rd cycle of CBCT, serum creatinine levels were significantly higher than at baseline, whereas mean creatinine clearances and estimated glomerular filtration rates were significantly lower. These renal function indicators also tended to be lower than baseline after the 6th–21st cycles, but these decreases were not significant. Significant AEs (≥grade 2) occurred in 10 patients (16.7%), and serious AEs (≥grade 3) developed in two that required temporary hemodialysis. Univariate analysis revealed that a low estimated glomerular filtration rate at baseline was related to the occurrence of a significant renal AE with borderline significance (Hazard ratio = 3.284, P = 0.100). The overall tumor response rate was 30.2%, and tumor response rates of 1st, 2nd, and 3rd line therapies were 36.4, 25.0, and 12.5%, respectively.

Conclusions

Cisplatin-based chemotherapy can be administered in the majority of patients with UUT-UC with a solitary kidney after nephroureterectomy without inducing a serious AE, and provides acceptable efficacy.

Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52:594–601PubMedCrossRef

Langner C, Hutterer G, Chromecki T, Winkelmayer I, Rehak P, Zigeuner R (2006) pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract. Mod Pathol 19:272–279PubMedCrossRef

Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E et al (2009) Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115:1224–1233PubMedCrossRef

Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182:900–906PubMedCrossRef

Uhm JE, Lim HY, Kim WS, Choi HY, Lee HM, Park BB et al (2007) Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia 9:18–22PubMedCrossRef

von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077PubMed

Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073PubMed

Poggio ED, Wang X, Weinstein DM, Issa N, Dennis VW, Braun WE et al (2006) Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 6:100–108PubMedCrossRef

Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0. http://ctep.info.nih.gov/reporting/ctc.html. http://ctep.info.nih.gov/reporting/ctc.html

10.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

11.

Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7:735–740PubMedCrossRef

12.

Lucas SM, Stern JM, Adibi M, Zeltser IS, Cadeddu JA, Raj GV (2008) Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques. J Urol 179:75–79 (discussion 79–80)PubMedCrossRef

13.

Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506–513PubMedCrossRef

14.

Raj GV, Iasonos A, Herr H, Donat SM (2006) Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 24:3095–3100PubMedCrossRef

15.

Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21:33–64PubMedCrossRef

16.

Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464PubMedCrossRef

17.

Garcia JA, Dreicer R (2006) Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 24:5545–5551PubMedCrossRef

18.

Petrioli R, Frediani B, Manganelli A, Barbanti G, De Capua B, De Lauretis A et al (1996) Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77:344–351PubMedCrossRef

19.

Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B et al (1997) Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966–1972PubMedCrossRef

20.

Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52:134–141PubMedCrossRef

21.

Culine S (2007) Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin? Eur Urol 52:9–10PubMedCrossRef

22.

Herget-Rosenthal S, Bokenkamp A, Hofmann W (2007) How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 40:153–161PubMedCrossRef

23.

Sambataro M, Thomaseth K, Pacini G, Robaudo C, Carraro A, Bruseghin M et al (1996) Plasma clearance rate of 51Cr-EDTA provides a precise and convenient technique for measurement of glomerular filtration rate in diabetic humans. J Am Soc Nephrol 7:118–127PubMed

24.

Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17PubMedCrossRef

25.

Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15:364–369PubMedCrossRef

26.

Han KS, Joung JY, Kim TS, Jeong IG, Seo HK, Chung J et al (2008) Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer 98:86–90PubMedCrossRef

Titel: Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract
verfasst von: Kang Su Cho
Jae Young Joung
Ho Kyung Seo
In-Chang Cho
Han Soo Chung
Jinsoo Chung
Kang Hyun Lee
Publikationsdatum: 01.04.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1349-2

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract